https://scholars.lib.ntu.edu.tw/handle/123456789/547196
標題: | Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma | 作者: | YU-LI CHEN WEN-FANG CHENG Chang M.-C. Lin H.-W. Huang C.-T. CHUNG-LIANG CHIEN CHI-AN CHEN |
公開日期: | 2013 | 出版社: | Academic Press Inc. | 卷: | 131 | 期: | 1 | 起(迄)頁: | 63-68 | 來源出版物: | Gynecologic Oncology | 摘要: | Objective. The ovarian cancer-associated ascites is an idealmaterial for evaluating the interaction between the host immune system and cancer cells in the tumor micro-environment. The aim of this study was to investigate whether the selected target cytokine expression levels in ascites could serve as an immune biomarker for predicting outcomes in ovarian cancer. Methods. Eighty-eight specimens of ovarian cancer-associated ascites were evaluated to select the target cytokine by a cytokine profiling kit. The 144 total samples were subsequently analyzed for this target cytokine. The correlation between the target cytokine and clinical characteristics was analyzed. Results. Interferon-gamma (IFN-γ) was identified as the target cytokine. Higher levels of IFN-γ in the ascites of the tumor micro-environment were associatedwith advanced disease (p = 0.012), higher tumor histological grading (p = 0.004), and sub-optimal surgical status (p = 0.040). By multivariate analysis, the adjusted hazard ratios (HRs) were 2.74 (95% confidence interval (CI) 1.85-4.05, p b 0.001) for disease-free survival (DFS) and 1.72 (95% CI 1.01-2.93, p = 0.048) for overall survival (OS) for a 10-fold increase in IFN-γ concentration in the ascites. An inverse dose-response relationship between IFN-γ level and survival was also noted (Ptrend b 0.001 for DFS and Ptrend b 0.042 for OS). Conclusions. Patients with ovarian cancer and higher IFN-γ expression levels in cancer-associated ascites will have shorter DFS and OS. IFN-γ levels in the ascites may be a prognostic marker and a potential reference for immunotherapy targeting IFN-γ. ? 2013 Elsevier Inc. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885295979&doi=10.1016%2fj.ygyno.2013.07.105&partnerID=40&md5=9e268846e560661dbc85f4d64a551055 https://scholars.lib.ntu.edu.tw/handle/123456789/547196 |
DOI: | 10.1016/j.ygyno.2013.07.105 | SDG/關鍵字: | biological marker; gamma interferon; interleukin 1 receptor blocking agent; interleukin 10; interleukin 12; interleukin 2; interleukin 3; interleukin 4; interleukin 6; interleukin 8; tumor necrosis factor alpha; adult; aged; article; ascites; ascites fluid analysis; cancer grading; cancer growth; cancer prognosis; cancer survival; clear cell carcinoma; controlled study; cytokine release; cytoreductive surgery; disease free survival; endometrioid adenocarcinoma.; endometrioid carcinoma; female; human; major clinical study; medical record review; mucinous adenocarcinoma; outcome assessment; ovary adenocarcinoma; ovary carcinoma; overall survival; predictive value; priority journal; protein blood level; protein expression; protein targeting; serous adenocarcinoma; tumor microenvironment |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。